Copenhagen, Denmark – October 12, 2017: IO Biotech, a private company developing novel immuno-oncology therapies targeting immune checkpoint inhibitory targets to treat cancer, today announced encouraging five year clinical data for novel next generation Immuno-Oncology therapy in lung cancer presented at ESMO 2017 Congress
